Abstract | OBJECTIVE: METHODS: We performed a case control study in 3 MELAS siblings (m.3243A>G tRNA(leu(UUR)) in MTTL1 gene) with different % blood mutant mtDNA to evaluate total body maximal aerobic capacity (VO(2peak)) using graded cycle ergometry and muscle metabolism using 31P-MRS. We then ran a clinical trial pilot study in MELAS sibs to assess response of these parameters to single dose and a 6-week steady-state trial of oral L-Arginine. RESULTS: At baseline (no L-Arg), MELAS had lower serum Arg (p = 0.001). On 3(1)P-MRS muscle at rest, MELAS subjects had increased phosphocreatine (PCr) (p = 0.05), decreased ATP (p = 0.018), and decreased intracellular Mg(2+) (p = 0.0002) when compared to matched controls. With L-arginine therapy, the following trends were noted in MELAS siblings on cycle ergometry: (1) increase in mean % maximum work at anaerobic threshold (AT) (2) increase in % maximum heart rate at AT (3) small increase in VO(2peak). On (31)P-MRS the following mean trends were noted: (1) A blunted decrease in pH after exercise (less acidosis) (2) increase in Pi/PCr ratio ( ADP) suggesting increased work capacity (3) a faster half time of PCr recovery (marker of mitochondrial activity) following 5 minutes of moderate intensity exercise (4) increase in torque. SIGNIFICANCE: These results suggest an improvement in aerobic capacity and muscle metabolism in MELAS subjects in response to supplementation with L-Arg. Intramyocellular hypomagnesemia is a novel finding that warrants further study. CLASSIFICATION OF EVIDENCE: Class III evidence that L-arginine improves aerobic capacity and muscle metabolism in MELAS subjects. TRIAL REGISTRATION: ClinicalTrials.gov NCT01603446.
|
Authors | Lance H Rodan, Greg D Wells, Laura Banks, Sara Thompson, Jane E Schneiderman, Ingrid Tein |
Journal | PloS one
(PLoS One)
Vol. 10
Issue 5
Pg. e0127066
( 2015)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25993630
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphocreatine
- phosphocreatinine
- Arginine
|
Topics |
- Adolescent
- Arginine
(pharmacology, therapeutic use)
- Case-Control Studies
- Dose-Response Relationship, Drug
- Ergometry
- Exercise
(physiology)
- Female
- Humans
- MELAS Syndrome
(drug therapy, metabolism, physiopathology)
- Magnetic Resonance Spectroscopy
- Male
- Muscles
(drug effects, metabolism)
- Neuroimaging
- Phosphocreatine
(analogs & derivatives, metabolism)
- Rest
(physiology)
- Young Adult
|